Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination

Vaccine

Volumn 26, Issue 50, 2008, Pages 6433-6440

  Kim, Sung Guh ^a   Park, Mi Young ^a   Kim, Chang Hyun ^a   Sohn, Hyun Jung ^a   Kim, Hye Sung ^a   Park, Jung Sun ^a   Kim, Hyung Jin ^a   Oh, Seong Taek ^a   Kim, Tai Gyu ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Anti tumor immunity; Calreticulin; Carcinoembryonic antigen; Dendritic cells; HIV TAT

Indexed keywords

CALRETICULIN; CALRETICULIN TRANSACTIVATOR PROTEIN CARCINOEMBRYONIC ANTIGEN FUSION PROTEIN; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; MESSENGER RNA; RNA; SIGNAL PEPTIDE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; ELECTROPORATION; FEMALE; FUSION GENE; GENE EXPRESSION; GENETIC CODE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MODIFICATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ADENOCARCINOMA; ANIMALS; CALRETICULIN; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DENDRITIC CELLS; ELECTROPORATION; GENE PRODUCTS, TAT; HUMANS; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; VACCINATION;

EID: 55749108698     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.072     Document Type: Article

References (40)

1. Thompson J.A., Grunert F., and Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5 5 (1991) 344-366
2. Facciabene A., Aurisicchio L., and La Monica N. Baculovirus vectors elicit antigen-specific immune responses in mice. J Virol 78 16 (2004) 8663-8672
3. Hodge J.W., McLaughlin J.P., Kantor J.A., and Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15 6-7 (1997) 759-768
4. Kantor J., Irvine K., Abrams S., Kaufman H., DiPietro J., and Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 84 14 (1992) 1084-1091
5. Cho H.I., Kim H.J., Oh S.T., and Kim T.G. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 22 2 (2003) 224-236
6. Oh S.T., Kim C.H., Park M.Y., Won E.H., Sohn H.J., Cho H.I., et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 24 15 (2006) 2860-2868
7. Matsuda K., Tsunoda T., Tanaka H., Umano Y., Tanimura H., Nukaya I., et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 53 7 (2004) 609-616
8. Godelaine D., Carrasco J., Lucas S., Karanikas V., Schuler-Thurner B., Coulie P.G., et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171 9 (2003) 4893-4897
9. Nair S.K., Morse M., Boczkowski D., Cumming R.I., Vasovic L., Gilboa E., et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235 4 (2002) 540-549
10. Lambert L.A., Gibson G.R., Maloney M., Durell B., Noelle R.J., and Barth Jr. R.J. Intranodal vaccination with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61 2 (2001) 641-646
11. Bergant M., Meden L., Repnik U., Sojar V., Stanisavljević D., and Jeras M. Preparation of native and amplified tumour RNA for dendritic cell transfection and generation of in vitro anti-tumour CTL responses. Immunobiology 211 3 (2006) 179-189
12. Liao X., Li Y., Bonini C., Nair S., Gilboa E., Greenberg P.D., et al. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 9 5 (2004) 757-764
13. Kim C.H., Yoon J.S., Sohn H.J., Kim C.K., Paik S.Y., Hong Y.K., et al. Direct vaccination with pseudotype baculovirus expressing murine telomeraseinduces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model. Cancer Lett 250 2 (2007) 276-283
14. + cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther 13 13 (2006) 1027-1036
15. + regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells. Mol Ther 12 5 (2005) 922-932
16. Lund L.H., Andersson K., Zuber B., Karlsson A., Engström G., Hinkula J., et al. Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. Cancer Gene Ther 10 5 (2003) 365-376
17. Mitsui H., Inozume T., Kitamura R., Shibagaki N., and Shimada S. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol 126 8 (2006) 1804-1812
18. Shibagaki N., and Udey M.C. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 33 4 (2003) 850-860
19. Peng S., Trimble C., He L., Tsai Y.C., Lin C.T., Boyd D.A., et al. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther 13 1 (2006) 67-77
20. Cheng W.F., Hung C.F., Chai C.Y., Hsu K.F., He L., Ling M., et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108 5 (2001) 669-678
21. Williams D.B. Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum. J Cell Sci 119 Pt 4 (2006) 615-623
22. 2+-binding chaperone of the endoplasmic reticulum. Int J Biochem Cell Biol 37 2 (2005) 260-266
23. Nair S., Wearsch P.A., Mitchell D.A., Wassenberg J.J., Gilboa E., and Nicchitta C.V. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol 162 11 (1999) 6426-6432
24. Basu S., and Srivastava P.K. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 189 5 (1999) 797-802
25. Robbins P.F., Kantor J.A., Salgaller M., Hand P.H., Fernsten P.D., and Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51 14 (1991) 3657-3662
26. Heiser A., Dahm P., Yancey D.R., Maurice M.A., Boczkowski D., Nair S.K., et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 164 10 (2000) 5508-5514
27. Namba Y., Usami M., and Suzuki O. Highly sensitive electrochemiluminescence immunoassay using the ruthenium chelate-labeled antibody bound on the magnetic microbeads. Anal Sci 11 15 (1999) 1087
28. Basu S., Binder R.J., Ramalingam T., and Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14 3 (2001) 303-313
29. Batchu R.B., Moreno A.M., Szmania S.M., Bennett G., Spagnoli G.C., Ponnazhagan S., et al. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res 65 21 (2005) 10041-10049
30. Shibagaki N., and Udey M.C. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 168 5 (2002) 2393-2401
31. Cho H.I., Kim E.K., Park S.Y., Lee S.K., Hong Y.K., and Kim T.G. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett 258 2 (2007) 189-198
32. Kim C.H., Woo S.J., Park J.S., Kim H.S., Park M.Y., Park S.D., et al. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 122 4 (2007) 615-622
33. Peng S., Tomson T.T., Trimble C., He L., Hung C.F., and Wu T.C. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther 13 3 (2006) 257-265
34. + T lymphocytes generated from a DNA vaccine control tumors through the Fas-FasL pathway. Mol Ther 12 5 (2005) 960-968
35. Solheim J.C., Harris M.R., Kindle C.S., and Hansen T.H. Prominence of beta 2-microglobulin, class I heavy chain conformation, and tapasinin the interactions of class I heavy chain with calreticulin and the transporter associated with antigen processing. J Immunol 158 5 (1997) 2236-2241
36. Sadasivan B., Lehner P.J., Ortmann B., Spies T., and Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5 2 (1996) 103-114
37. Fu T.M., Mylin L.M., Schell T.D., Bacík I., Russ G., Yewdell J.W., et al. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol 72 2 (1998) 1469-1481
38. Restifo N.P., Bacík I., Irvine K.R., Yewdell J.W., McCabe B.J., Anderson R.W., et al. Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol 154 9 (1995) 4414-4422
39. Bak S.P., Amiel E., Walters J.J., and Berwin B. Calreticulin requires an ancillary adjuvant for the induction of efficient cytotoxic T cell responses. Mol Immunol 45 5 (2008) 1414-1423
40. + T cells in anti-tumor immune responses. Immunol Rev 222 (2008) 129-144